91 related articles for article (PubMed ID: 23686095)
1. Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.
Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lambie A; Lipton JH; Loach D; Messner HA
Bone Marrow Transplant; 2013 Nov; 48(11):1450-5. PubMed ID: 23686095
[TBL] [Abstract][Full Text] [Related]
2. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.
Michelis FV; Messner HA; Atenafu EG; McGillis L; Lambie A; Uhm J; Alam N; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Bone Marrow Transplant; 2015 Nov; 50(11):1405-10. PubMed ID: 26168067
[TBL] [Abstract][Full Text] [Related]
3. Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
Michelis FV; Messner HA; Atenafu EG; Kim DD; Kuruvilla J; Lipton JH; Uhm J; Loach D; Gupta V
Biol Blood Marrow Transplant; 2014 Apr; 20(4):474-9. PubMed ID: 24345422
[TBL] [Abstract][Full Text] [Related]
4. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.
Imahashi N; Suzuki R; Fukuda T; Kakihana K; Kanamori H; Eto T; Mori T; Kobayashi N; Iwato K; Sakura T; Ikegame K; Kurokawa M; Kondo T; Iida H; Sakamaki H; Tanaka J; Kawa K; Morishima Y; Atsuta Y; Miyamura K
Bone Marrow Transplant; 2013 Jan; 48(1):56-62. PubMed ID: 22705800
[TBL] [Abstract][Full Text] [Related]
7. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning.
Sengeløv H; Gerds TA; Brændstrup P; Kornblit B; Mortensen BK; Petersen SL; Vindeløv LL
Bone Marrow Transplant; 2013 Sep; 48(9):1185-91. PubMed ID: 23524638
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
[TBL] [Abstract][Full Text] [Related]
10. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
[TBL] [Abstract][Full Text] [Related]
11. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.
Chevallier P; Labopin M; Milpied N; Cornelissen JJ; Blaise D; Petersen E; Sandstedt A; Goker H; Socie G; Rocha V; Mohty M;
Bone Marrow Transplant; 2012 Nov; 47(11):1442-7. PubMed ID: 22504932
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
14. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.
Kurosawa S; Yamaguchi T; Uchida N; Miyawaki S; Usuki K; Watanabe M; Yamashita T; Kanamori H; Tomiyama J; Nawa Y; Yano S; Takeuchi J; Yakushiji K; Sano F; Uoshima N; Yano T; Nannya Y; Moriuchi Y; Miura I; Takaue Y; Fukuda T
Biol Blood Marrow Transplant; 2011 Mar; 17(3):401-11. PubMed ID: 20667478
[TBL] [Abstract][Full Text] [Related]
15. Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.
Michelis FV; Messner HA; Uhm J; Alam N; Lambie A; McGillis L; Seftel MD; Gupta V; Kuruvilla J; Lipton JH; Kim DD
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e73-81. PubMed ID: 25458081
[TBL] [Abstract][Full Text] [Related]
16. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
17. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
18. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
[TBL] [Abstract][Full Text] [Related]
19. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
20. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
